Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 421-820-9 | CAS number: 192268-65-8 CD 28-0132; IRGALUBE 232
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 995
- Report date:
- 1995
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- Version / remarks:
- 92/69/EWG, B.6 (Guinea Pig maximization test (GPMT))
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- Currently no LLNA study is available for assessment. The Guinea Pig Maximization Test (GPMT) has been carried out as an animal test to predict human sensitization for over a decade and is recommended by international test guidelines such as OECD.
Test material
- Reference substance name:
- A mixture of: triphenylthiophosphate and tertiary butylated phenyl derivatives
- EC Number:
- 421-820-9
- EC Name:
- A mixture of: triphenylthiophosphate and tertiary butylated phenyl derivatives
- Cas Number:
- 192268-65-8
- Molecular formula:
- Unspecified
- IUPAC Name:
- O,O,O-triphenyl phosphorothioate; O-2,4-di-tert-butylphenyl O,O-diphenyl phosphorothioate; O-2-tert-butylphenyl O,O-diphenyl phosphorothioate; O-2-tert-butylphenyl O-4-tert-butylphenyl O-phenyl phosphorothioate; O-4-tert-butylphenyl O,O-diphenyl phosphorothioate
- Details on test material:
- - Appearance: yellowish liquid.
- Storage condition of test material: Room temperature in dark
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- male
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: D. Hall, Newchurch, Staffordshire, England.
- Age at study initiation: Approximately four to five weeks of age.
- Weight at study initiation: 292 to 339 g.
- Housing: in groups of five in suspended metal cages with wire mesh floors
- Diet: ad libitum (A vitamin C enriched guinea-pig diet FD2; hay was given weekly) diet was not analysed for nutrients, possible contaminants or microorganisms.
- Water: ad libitum (analysed weekly for contamination).
- Acclimation period: For five days prior to allocation to the main study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.
- Humidity (%): 30 - 70.
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
An additional six animals, from the same supplier, were used for the preliminary investigations.
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal
- Vehicle:
- coconut oil
- Concentration / amount:
- 1 % v/v in Alembicol D (A product of coconut oil, supplied by Alembic Products, Saltney, Chester, England)
- Route:
- epicutaneous, occlusive
- Concentration / amount:
- 100 %
Challenge
- No.:
- #1
- Route:
- epicutaneous, occlusive
- Vehicle:
- coconut oil
- Concentration / amount:
- 100 % and 50 % v/v in Alembicol D.
- No. of animals per dose:
- Number of animals in test group: 10Number of animals in negative control group: 5
- Details on study design:
- RANGE FINDING TESTS:
Animals for these investigations were pre-treated with an intradermal injection of Freund's complete adjuvant, 50:50 with water for irrigation (Ph. Eur), approximately two weeks prior to the start of the preliminary investigations.
MAIN STUDY
A. INDUCTION EXPOSURE
Intradermal Injection
- Site/Area: Back (scapular region)/2 x 4 cm
- No. of injections/animal: 6 injections in pairs each.
- Test substance group (cranial; 2 injections side by side): Freund's complete adjuvant (FCA) blended (1:1, v/v) with water (Ph.Eur.).
- Test substance group (middle; 2 injections side by side): The test article (1%) in vehicle.
- Test substance group (caudal; 2 injections side by side): 50% Freund's complete adjuvant blended (1:1, v/v) with water + 1 % test article in vehicle.
- Control group (cranial; 2 injections side by side): Freund's complete adjuvant (FCA) blended (1:1, v/v) with water (Ph.Eur.).
- Control group (middle; 2 injections side by side): Vehicle.
- Control group (caudal; 2 injections side by side): 50% Freund's complete adjuvant blended (1:1, v/v) with water + vehicle
- Volume per injection: 0.1 ml
- Evaluation (hr after injection): from 24 hour till day 7
- Exposure period: Single exposure
Epicutaneous induction exposure
- Time schedule: 7 days after intradermal injection
- Site: same as intradermal injections (site was pretreated 24 hours before with 0.5 ml per site of 10% w/w sodium lauryl sulphate in petrolatum)
- Frequency of applications: Once.
- Area of application: 2 x 4 cm (on Whatman No. 3)
- Concentrations: undiluted test article (test group) and water (control group)
- Volume applied: 0.4ml/animal
- Type of coverage: occlusive (impemeable plastic adhesive tape (50 ram width "Blenderm") + adhesive bandage (50 mm width "Elastoplast")
- Duration: 48 hours
- Evaluation (hr after challenge): directly after removal of patchB.
CHALLENGE EXPOSURE (all animals)
- Frequency of exposure: once
- Time schedule: 2 weeks after termination of induction exposures
- Site: left flank
- Area of application: 2 x 2 cm (Whatman No. 3 paper)
- Concentrations: undiluted (anterior flank) and 50% (v/v) in vehicle- Volume applied: 0.2 ml/animal
- Type of coverage: occlusive (impemeable plastic adhesive tape (50 ram width "Blenderm") + adhesive bandage (50 mm width "Elastoplast")
- Duration: 24 hours
- Evaluation (hr after challenge): 24 and 48 hours after termination of exposure
SCORING SYSTEM:
OECD Draize system
Erythema and eschar formation:
No erythema 0
Slight erythema 1
Well-defined erythema 2
Moderate erythema 3
Severe erythema (beet redness) to slight eschar formation (injuries in depth) 4
Oedema formation:
No oedema 0
Slight oedema 1
Well-defined (edges of area well defined by definite raising) 2
Moderate oedema (raised approximately 1 millimetre) 3
Severe oedema (raised more than 1 millimetre and extending beyond the area of exposure) 4
OTHER
All animals were observed daily for signs of ill health or toxicity. The body weight of each guinea-pig on the main study was recorded on Day 1 (day of intradermal injections) and on the last day observations were made of dermal responses to the challenge applications. - Positive control substance(s):
- yes
- Remarks:
- hexyl cinnamic aldehyde (CAS No. 101-86-0)
Results and discussion
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 100 %
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Refer to Table 2
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 50 %
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Refer to Table 2
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 100 %
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Refer to Table 2
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 50 %
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Refer to Table 2
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 100 %
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- Refer to Table 2
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 50 %
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- Refer to Table 2
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 100 %
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- Refer to Table 2
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 50 %
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- Refer to Table 2
- Group:
- positive control
- Remarks on result:
- other: see Table 1
Any other information on results incl. tables
Table 1:
M&K R&D No. |
Number of animals |
Dates of study |
Dates of receipt of HCA |
Dose levels % (aqueous dilutions) |
Results |
||||||
Induction |
Challenge |
||||||||||
Test |
Control |
Start |
Finish |
Intradermal |
Topical |
Positive |
Inconclusive |
Negative |
|||
1 |
10 |
5 |
08.12.92 |
09.01.93 |
29.10.92 |
10 |
As Supplied |
As supplied and 50 |
10/10 |
0/10 |
0/10 |
IE |
10 |
10 |
20.07.93 |
16.08.93 |
11.06.93 |
10 |
As Supplied |
As supplied and 50 |
9/10 |
0/10 |
1/10 |
2A |
10 |
10 |
15.03.94 |
11.04.94 |
11.06.93 |
10 |
As Supplied |
As supplied and 50 |
10/10 |
0/10 |
0/10 |
2D |
10 |
10 |
06.09.94 |
01.10.94 |
12.08.94 |
10 |
As Supplied |
As supplied and 50 |
9/10 |
0/10 |
1/10 |
2G* |
10 |
10 |
28.09.94 |
23.10.94 |
12.08.94 |
10 |
As Supplied |
As supplied and 50 |
10/10 |
0/10 |
0/10 |
2H |
10 |
10 |
05.10.94 |
30.10.94 |
12.08.94 |
10 |
As Supplied |
As supplied and 50 |
10/10 |
0/10 |
0/10 |
3A |
10 |
10 |
24.01.95 |
18.02.95 |
24.10.94 |
10 |
As Supplied |
As supplied and 50 |
8/10 |
1/10 |
1/10 |
Animals supplied by D. Hall Newchurch.
* Animals supplied by Interfauna (UK) Ltd.
Hexyl cinnamic aldehyde obtained from Aldrich Chemicals Co.
Table 2. Dermal reactions observed after each induction
Site |
Intradermal injection |
Topical application |
||
Test animals |
Control animals |
Test animals |
Control animals |
|
1 |
Necrosis |
Necrosis |
Slight erythema |
Slight erythema |
2 |
Slight irritation |
Slight irritation |
||
3 |
Necrosis |
Necrosis |
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.